https://www.biopharmawatch.com/news/ALC/systane-pro-preservative-free-launch-canada BiopharmaWatch en 2026-09-28T14:15:00.000Z Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief https://www.biopharmawatch.com/news/NTHI/neonc-brain-cancer-pipeline-advances BiopharmaWatch en 2026-09-28T13:51:00.000Z Powerful NeOnc Brain Cancer Pipeline Advances https://www.biopharmawatch.com/news/ONCY/oncolytics-reo-033-colorectal-cancer-study-update BiopharmaWatch en 2026-09-28T13:30:00.000Z Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study https://www.biopharmawatch.com/news/ESYN/enersyn-global-nigeria-energy-investment-lagos-cng-project BiopharmaWatch en 2026-09-28T13:10:00.000Z EnerSyn Global Inc. Announces Second Nigeria Energy Investment: Lagos CNG Mother Station Project https://www.biopharmawatch.com/news/HYPD/hyperion-defi-d3-frontier-vault-launch BiopharmaWatch en 2026-09-28T13:06:00.000Z Hyperion DeFi Supports D3’s Frontier Vault Launch, Bringing Internet Domain Priority Access to the Hyperliquid Ecosystem https://www.biopharmawatch.com/news/MMED/minimed-appoints-sheila-denton-general-counsel BiopharmaWatch en 2026-09-28T13:03:00.000Z MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary https://www.biopharmawatch.com/news/CV/capsovision-fda-clearance-ai-highlights-capsocam-plus BiopharmaWatch en 2026-09-28T13:00:00.000Z CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus® https://www.biopharmawatch.com/news/PALI/palisade-bio-presents-pali-2108-ueg-week-2026 BiopharmaWatch en 2026-09-28T12:50:00.000Z Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026 https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-acquisition-webster-equity-partners BiopharmaWatch en 2026-09-28T12:45:00.000Z Lifecore Biomedical to be Acquired by Webster Equity Partners https://www.biopharmawatch.com/news/GRI/gri-bio-ipf-summit-2026-insights BiopharmaWatch en 2026-09-28T12:40:00.000Z GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-positive-preclinical-findings-sil204 BiopharmaWatch en 2026-09-28T12:30:00.000Z Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-cheast-2026 BiopharmaWatch en 2026-09-28T12:30:00.000Z Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026 https://www.biopharmawatch.com/news/CARL/carlsmed-appoints-richard-heppenstall-cfo BiopharmaWatch en 2026-09-28T12:30:00.000Z Carlsmed Appoints Richard Heppenstall as Chief Financial Officer https://www.biopharmawatch.com/news/IGC/igc-pharma-completes-enrollment-phase-2-calma-trial BiopharmaWatch en 2026-09-28T12:23:06.000Z IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026 https://www.biopharmawatch.com/news/DARE/dare-bioscience-new-patent-dare-hpv-program BiopharmaWatch en 2026-09-28T12:20:00.000Z Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection https://www.biopharmawatch.com/news/HYPR/hyperfine-expands-global-access-portable-brain-mri BiopharmaWatch en 2026-09-28T12:15:00.000Z Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets https://www.biopharmawatch.com/news/PBM/psyence-biomed-exclusive-ibogaine-license BiopharmaWatch en 2026-09-28T12:11:20.000Z Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation https://www.biopharmawatch.com/news/LABT/lakewood-amendex-nu-3-positive-data-diabetic-foot-ulcers BiopharmaWatch en 2026-09-28T12:02:00.000Z Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers https://www.biopharmawatch.com/news/NTHI/neonc-technologies-fda-end-of-phase-1-meeting-ne0212 BiopharmaWatch en 2026-09-28T12:00:42.000Z NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 https://www.biopharmawatch.com/news/NKTR/nektar-rezpegaldesleukin-eadv-2026-presentations BiopharmaWatch en 2026-09-28T12:00:00.000Z Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026 https://www.biopharmawatch.com/news/LNTH/lantheus-sparrow-phase-2-3-trial-prostate-cancer BiopharmaWatch en 2026-09-28T12:00:00.000Z Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-phase-3-azure-1-study-brelovitug BiopharmaWatch en 2026-09-28T12:00:00.000Z Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus https://www.biopharmawatch.com/news/TMO/thermo-fisher-earnings-conference-call-october-2026 BiopharmaWatch en 2026-09-28T12:00:00.000Z Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026 https://www.biopharmawatch.com/news/NCEL/newcelx-attends-breakthrough-t1d-congress-2026 BiopharmaWatch en 2026-09-28T12:00:00.000Z NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes https://www.biopharmawatch.com/news/ALXO/alx-oncology-evorpacept-gastric-cancer-data BiopharmaWatch en 2026-09-28T12:00:00.000Z ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer https://www.biopharmawatch.com/news/FDMT/4dmt-phase-3-trial-4d-150-dme BiopharmaWatch en 2026-09-28T12:00:00.000Z 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME https://www.biopharmawatch.com/news/KROS/keros-therapeutics-phase-2-dosing-rinvatercept-dmd BiopharmaWatch en 2026-09-28T12:00:00.000Z Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD https://www.biopharmawatch.com/news/HUMA/humacyte-expands-board-expertise-scott-coward-paul-kuznik BiopharmaWatch en 2026-09-28T12:00:00.000Z Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-expands-laboratory-capabilities BiopharmaWatch en 2026-09-28T12:00:00.000Z Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research https://www.biopharmawatch.com/news/ABBV/fda-approves-abbvie-juvmo-parkinsons-disease BiopharmaWatch en 2026-09-28T12:00:00.000Z U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease https://www.biopharmawatch.com/news/PVLA/fda-funding-qtorin-rapamycin-microcystic-lymphatic-malformations BiopharmaWatch en 2026-09-28T11:30:09.000Z U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations https://www.biopharmawatch.com/news/CGC/canopy-growth-appoints-sebastian-bloete-germany-manager BiopharmaWatch en 2026-09-28T11:30:00.000Z Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany https://www.biopharmawatch.com/news/BHVN/biohaven-bhv-1530-eortc-nci-aacr-symposium-2026 BiopharmaWatch en 2026-09-28T11:30:00.000Z Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 https://www.biopharmawatch.com/news/IMRX/immuneering-2026-aacr-conference-atebimetinib-pancreatic-cancer BiopharmaWatch en 2026-09-28T11:30:00.000Z Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-appoints-yariv-houvras-cmo BiopharmaWatch en 2026-09-28T11:30:00.000Z Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer https://www.biopharmawatch.com/news/SCYX/scynexis-barda-contract-funding-scy-247 BiopharmaWatch en 2026-09-28T11:30:00.000Z SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-fda-removal-drug-limit BiopharmaWatch en 2026-09-28T11:30:00.000Z CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit https://www.biopharmawatch.com/news/MBRX/moleculin-announces-cardiac-safety-analysis-annamycin BiopharmaWatch en 2026-09-28T11:00:25.000Z Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine https://www.biopharmawatch.com/news/NAIA/naia-relief-alumni-perks-partnership-well-being-support BiopharmaWatch en 2026-09-28T11:00:00.000Z naia Relief Inc. Announces Strategic Partnership with Alumni-Perks to Expand Access to 24/7 Well-Being Support for Canadian University/College Alumni https://www.biopharmawatch.com/news/BRKR/bruker-advances-functional-proteomics-timsultra-timsomni BiopharmaWatch en 2026-09-28T11:00:00.000Z Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research https://www.biopharmawatch.com/news/ANTX/antx-funding-extension-tuberculosis-research-gsk BiopharmaWatch en 2026-09-28T11:00:00.000Z AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK https://www.biopharmawatch.com/news/CSTL/tissuecypher-study-management-non-dysplastic-barretts-esophagus BiopharmaWatch en 2026-09-28T11:00:00.000Z New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-banyan-trial-als-foralumab BiopharmaWatch en 2026-09-28T11:00:00.000Z Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-virtual-kol-event-denifanstat-update BiopharmaWatch en 2026-09-28T11:00:00.000Z Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026 https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-bh-501284-aacr-conference BiopharmaWatch en 2026-09-28T11:00:00.000Z BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer https://www.biopharmawatch.com/news/ARVN/arvinas-phase-1-2-trial-arv-6723 BiopharmaWatch en 2026-09-28T11:00:00.000Z Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-launches-impavido-capsules BiopharmaWatch en 2026-09-28T10:50:00.000Z Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules https://www.biopharmawatch.com/news/PFE/pfizer-advances-cancer-care-esmo-2026 BiopharmaWatch en 2026-09-28T10:45:00.000Z Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO https://www.biopharmawatch.com/news/MRK/merck-exclusive-license-agreement-sci-brunch-spr2015 BiopharmaWatch en 2026-09-28T10:45:00.000Z Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor https://www.biopharmawatch.com/news/ACET/adicet-bio-prula-cel-safety-efficacy-data-sle BiopharmaWatch en 2026-09-28T10:45:00.000Z Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis https://www.biopharmawatch.com/news/KOD/zenkuda-tabirafusp-ted-daybreak-trial-wamd BiopharmaWatch en 2026-09-28T10:30:00.000Z Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria. https://www.biopharmawatch.com/news/WELL/well-health-wellstar-tsxv-listing-approval BiopharmaWatch en 2026-09-28T10:00:00.000Z WELL Health Subsidiary WELLSTAR Announces Conditional Approval for TSXV Listing and Files Filing Statement https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-dr-michael-white-promotion BiopharmaWatch en 2026-09-28T10:00:00.000Z IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development https://www.biopharmawatch.com/news/ZYME/zymeworks-theravance-biopharma-acquisition-financial-guidance BiopharmaWatch en 2026-09-28T10:00:00.000Z Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition https://www.biopharmawatch.com/news/MNOV/medicinova-topline-results-mn-001-natg-202-trial BiopharmaWatch en 2026-09-28T10:00:00.000Z MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) https://www.biopharmawatch.com/news/YI/111-inc-establishes-special-committee BiopharmaWatch en 2026-09-28T08:30:00.000Z 111, Inc. Announces Establishment of the Special Committee https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-09-28 BiopharmaWatch en 2026-09-28T07:15:32.098Z IGALMI PDUFA for Agitation in Bipolar Disorder: Biotech Catalysts Sep 28, 2026 https://www.biopharmawatch.com/news/STAA/staars-consumer-survey-vision-correction-germany BiopharmaWatch en 2026-09-28T07:00:00.000Z Verbraucherumfrage von STAAR Surgical: 71 Prozent der Deutschen möchten auf Sehhilfen verzichten, kennen aber ihre Alternativen nicht https://www.biopharmawatch.com/news/TMO/thermo-fisher-evosep-reseller-agreement BiopharmaWatch en 2026-09-28T07:00:00.000Z Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno https://www.biopharmawatch.com/news/MEDS/datameds-ai-tollo-health-launch-health-lives-here-app BiopharmaWatch en 2026-09-28T06:00:00.000Z DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application https://www.biopharmawatch.com/news/DXCM/dexcom-report-easd-2026-diabetes-care-opportunity BiopharmaWatch en 2026-09-28T06:00:00.000Z Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care https://www.biopharmawatch.com/news/IVA/inventiva-reports-2026-first-half-financial-results BiopharmaWatch en 2026-09-28T06:00:00.000Z Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/QGEN/qiagen-fda-clearance-qiastat-dx-bacteria-panel BiopharmaWatch en 2026-09-28T05:30:00.000Z QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-2026-half-year-results-update BiopharmaWatch en 2026-09-28T05:00:00.000Z Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-investor-call-azure-1-study BiopharmaWatch en 2026-09-27T21:00:00.000Z Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 https://www.biopharmawatch.com/news/ARAY/accuray-samsung-neurologica-collaboration-cyberknife BiopharmaWatch en 2026-09-27T15:15:00.000Z Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform